Wednesday☕️

May 17, 2023 • 4 min read

Trending:

Markets/Economies:

AI Hearing:

Yesterday, OpenAI CEO Sam Altman appeared before the Senate to address concerns regarding artificial intelligence.
Several senators raised concerns about the technology's potential to imitate individuals. Another senator drew parallels with social media and emphasized the need for regulation.
In response, Altman acknowledged these concerns, stating, "We understand why people are worried about AI; we are, too." He proposed the establishment of a new government agency responsible for licensing AI technologies and ensuring that companies adhere to regulatory standards.
Altman also recognized the likelihood of AI replacing certain jobs and emphasized that it is the government's responsibility to address this issue and develop appropriate solutions.

Free IRS Tax Filing:

The Internal Revenue Service (IRS) is currently piloting an e-filing system designed to enable individuals to submit their tax returns directly and free of charge.
In the present, no government-sponsored service offers free or digital tax filing. Instead, individuals either hire accountants or resort to paid e-filing services like H&R Block and TurboTax. The IRS has sought advice from a think tank on how to develop its own free e-filing service.

UK Autonomous Bus:

On Monday, the United Kingdom launched its first full-sized, self-driving bus service for the public. Operating in Scotland, the AB1 service covers a 14-mile stretch between the Ferrytoll Park and Ride in Fife and the Edinburgh Park Transport Interchange.
The autonomous bus service, managed by public transport company Stagecoach, has the capacity to accommodate up to 10,000 passengers per week. The cost of a single adult ticket for a one-way journey is set at £7.20, equivalent to approximately $9.

Google AI Drug Discovery:

Yesterday, Google Cloud introduced two new AI tools specifically tailored for biotech and pharmaceutical firms.
The first tool, named the Target and Lead Identification Suite, is engineered to assist companies in predicting and comprehending the structure of proteins, a key aspect in the development of new drugs.
Meanwhile, the second tool, the Multiomics Suite, is designed to aid researchers in managing large volumes of genomic data, including ingestion, storage, analysis, and sharing.

Statistic: